Navigation Links
Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
Date:7/23/2008

bability of success, the interim analysis provides us with the potential to accelerate our BLA amendment for PROVENGE," said Mitchell H. Gold, president and chief executive officer of Dendreon.

If the IDMC reports in October that the pre-specified criterion for statistical significance is not met, then the company anticipates continuing the trial with the expectation of reporting final results in the second half of 2009.

About IMPACT Study Design

The IMPACT trial is a multicenter, randomized, double-blind, placebo- controlled Phase 3 study, which enrolled just over 500 men with metastatic, androgen independent prostate cancer with a primary endpoint of overall survival. Dendreon is conducting the IMPACT trial under a Special Protocol Assessment (SPA) agreed upon with the FDA.

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 186,320 new cases expected to be diagnosed in 2008, and approximately 28,660 men expected to die this year from the disease. Currently there are limited treatment options for men with advanced, metastatic prostate cancer.

About Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its experti
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
8. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
11. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Sept. 1, 2015 Sargas Pharmaceutical Adherence ... and Drug Adherence m Health applications along with ... process of non face-to-face monitoring of twenty minutes ... release of our apps, doctors are now well ... with our ONCHIT certified Physician, Pharmacy and Patient ...
(Date:9/1/2015)... Within just two years after reaching a ... reached 3,000 employees worldwide. This increase is reflecting ... drug delivery market and SHL,s effective commitment, productivity ... the design and manufacturing of auto injectors and ... capabilities, a lean supply chain, strong partnerships, and ...
(Date:9/1/2015)... 2015 Egalet Corporation (Nasdaq: EGLT ... focused on discovering, developing, and commercializing innovative pain ... scientific data on SPRIX ® (ketorolac tromethamine) ... product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral ... 2015 to be held September 8 to 12 ...
Breaking Medicine Technology:SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2SHL Group Reaches Major Milestone of 3000 Employees 2Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 2Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 3Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 4Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 5Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 6
... Inc., a privately-held therapeutic device company, today announced ... with Bezwada Biomedical to develop and commercialize Bezwada,s ... Biomedical is an innovation-driven company with proprietary technology ... polyamides derived from hydrolyzable isocyanates. This technology can ...
... Aug. 31, 2011 Assured Pharmacy, Inc. (Pink Sheets: ... that provide advanced prescription services to a diverse array ... it sold in a private placement to an accredited ... an aggregate principal amount of $400,000 due December 1, ...
Cached Medicine Technology:ORTHOCON Announces Signing of Exclusive, Worldwide License Agreement With Bezwada Biomedical 2Assured Pharmacy, Inc. Receives Gross Proceeds of $400,000 from Sale of Convertible Debentures and Warrants 2Assured Pharmacy, Inc. Receives Gross Proceeds of $400,000 from Sale of Convertible Debentures and Warrants 3
(Date:9/1/2015)... ... September 01, 2015 , ... Plaza ... the MonaLisa Touch® , an innovative vaginal health laser procedure that prevents ... new hormone-free treatment for atrophic vaginitis, a condition that causes vaginal dryness, pelvic ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... analysis of pet vital signs and activity, today announced its integration with leading ... most popular and widely-adopted veterinary hospital Practice Management Software packages in the US. ...
(Date:9/1/2015)... ... 01, 2015 , ... Royal River Natural Foods, a locally-owned independent natural health ... for 19 years and found that, among those who had a stroke, people who ... is part of the September 2015 issue of “Natural Insights for Well Being,” which ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Two of ... cross cultural relations through food and dining. , Recently named “the next big ... Luigi Diotaiuti are known for telling the whole story behind food and reclaiming culinary ...
(Date:9/1/2015)... ... , ... METTLER TOLEDO is pleased to announce that the ... EasySampler data is automatically transferred to, and reported with, the referring chemical synthesis ... EasySampler fully automates the sampling process including sampling capture, quench at ...
Breaking Medicine News(10 mins):Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 3
... during and after treatment resulted in less fatigue, greater ... - Exercise during and after treatment improves quality of ... or prostate cancer, a new study finds. , "Using ... potential to benefit patients both physically and psychologically, as ...
... ... 7,000 stores in under five months of operation. The site offers 30,000 coupons from 7,000 ... 500 votes per day, making it one of the fastest growing coupons/deals sites ever. ... (PRWEB) May 27, 2010 ...
... , THURSDAY, May 27 (HealthDay News) -- A new ... that many people don,t know enough about sun damage ... survey showed that despite our repeated warnings about the ... sun protection, many people could not correctly answer true/false ...
... ... and published by Random House Mondadori this ,practical guide teaches Latina women how to ... ... Guía Para Vestir Mejor (Discover Your Style: Your Guide to Dressing Better) written ...
... "color-coded" laboratory mice are providing researchers with a novel ... monitor the cellular immune responses of transplanted tissue in ... the June issue of Nature Medicine , which ... a key consideration in developing strategies to improve transplant ...
... at the UCLA Medical Center found that antiviral therapy ... is the most cost-effective approach to treating patients with ... Full details appear in the June issue of ... behalf of the American Association for the Study of ...
Cached Medicine News:Health News:Exercise Boosts Health of Cancer Patients 2Health News:Coupon Site TrimBack.com Adds 7000th Online Store 2Health News:Many People Still Don't Know How to Protect Against Skin Cancer 2Health News:"Descubre Tu Estilo: Tu Gua Para Vestir Mejor" Wins Triple Crown Award and Honors at the 12th International Latino Book Awards 2Health News:"Descubre Tu Estilo: Tu Gua Para Vestir Mejor" Wins Triple Crown Award and Honors at the 12th International Latino Book Awards 3Health News:Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue 2Health News:Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue 3Health News:Antiviral therapy during compensated cirrhosis most cost-effective approach 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: